H. Lundbeck A/S

Ottiliavej 9 Te DK-2500 Valby, Copenhagen Fa CVR number: 56759913 LEI code: 5493006R4KC20I5D3470

Tel +45 36 30 13 11 Fax +45 36 43 82 62 E-mail investor@lundbeck.com www.lundbeck.com



Corporate Release

Transactions with shares and linked securities in H. Lundbeck A/S made by executives and their closely associated parties

Valby, Denmark, 10 February 2023 – H. Lundbeck A/S (Lundbeck) hereby publishes and reports transactions made by executives and persons closely associated with them with shares and linked securities in Lundbeck.

1.	Details of the person discharging managerial responsibilities / person closely associated				
a)	Name	Johan Luthman			
2.	Reason for the notification				
a)	Position/status	Executive Vice President, Research & Development			
b)	Initial notification/Amendment	Initial notification			
3.	Details of the issuer, emission	, emission allowance market participant,			
	auction platform, auctioneer o	platform, auctioneer or auction monitor			
a)	Name	H. Lundbeck A/S			
b)	LEI code	5493006R4KC2OI5D3470			
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii)				
	ach type of transaction; (iii) each date; and (iv) each place where transactions have				
	been conducted				
a)	Description of the financial	Shares			
	instrument, type of instrument				
b)	Identification code	H. Lundbeck A/S, B-shares: DK0061804770			
b)	Nature of the transaction	Purchase of shares			
c)	Price(s) and volume(s)	Price(s)	Volume(s)		
		DKK 29.84	8,399		
d)	Aggregated information				
	- Aggregated volume				
	- Price				
e)	Date of the transaction	2023-02-10			
f)	Place of the transaction	NASDAQ Copenhagen XCSE			



1.	Details of the person discharging managerial responsibilities / person closely					
, ,	associated					
a)	Name	Jacob Tolstrup				
2.	Reason for the notification					
a)	Position/status	Executive Vice President, Commercial Operations				
b)	Initial notification/Amendment	Initial notification				
3.	Details of the issuer, emission allowance market participant,					
	auction platform, auctioneer of	on platform, auctioneer or auction monitor				
a)	Name	H. Lundbeck A/S				
b)	LEI code	5493006R4KC2OI5D3470				
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii)					
	each type of transaction; (iii) e	type of transaction; (iii) each date; and (iv) each place where transactions have				
	been conducted					
a)	Description of the financial	Shares				
	instrument, type of instrument					
	Identification code	H. Lundbeck A/S, A-shares: DK0061804697				
		H. Lundbeck A/S, B-shares: DK0061804770				
b)	Nature of the transaction	Sale of shares				
c)	Price(s) and volume(s)	Price(s)	Volume(s)			
		DKK 26.90 (A-shares)	A-shares: 7,536			
		DKK 29.04 (B-shares)	B-shares: 28,000			
d)	Aggregated information					
	- Aggregated volume					
	- Price					
e)	Date of the transaction	2023-02-09				
f)	Place of the transaction	NASDAQ Copenhagen XCSE				

Persons under an obligation to report are defined as members of the Executive Management, members of the Board of Directors and other executives of H. Lundbeck A/S and persons/entities closely associated to them.

Closely associated persons/entities means inter alia:

- spouse or cohabitant
- dependent children
- legal entities in which the executive has a controlling influence.



Lundbeck contacts

Investors: Palle Holm Olesen Vice President, Investor Relations PALO@lundbeck.com +45 30 83 24 26 Media: Thomas Mikkel Mortensen Media Relations Lead, Corporate Communication THMR@lundbeck.com +45 30 83 30 24

About H. Lundbeck A/S

Lundbeck is a global pharmaceutical company specialized in brain diseases. For more than 70 years, we have been at the forefront of neuroscience research. We are tirelessly dedicated to restoring brain health, so every person can be their best. We are committed to fighting stigma and discrimination against people living with brain diseases and advocating for broader social acceptance of people with brain health conditions. Our research programs tackle some of the most complex challenges in neuroscience, and our pipeline is focused on bringing forward transformative treatments for brain diseases for which there are few, if any therapeutic options.

For additional information, we encourage you to visit our corporate site www.lundbeck.com and connect with us on Instagram (h_lundbeck), Twitter at @Lundbeck and via LinkedIn.